Takeda announces favorable phase 3 safety and efficacy results of tak-755 as compared to standard of care in congenital thrombotic thrombocytopenic purpura (cttp)

Osaka, japan & cambridge, mass.--( business wire )--takeda (tse:4502/nyse:tak) today announced that the totality of evidence from a pre-planned interim analysis of a pivotal phase 3 study supports the efficacy and safety of tak-755 as enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cttp). cttp is an ultra-rare sub-type of thrombotic thrombocytopenic purpura (ttp), a rare, chronic and debilitating blood clotting disorder caused by a deficiency in adamts13 protease.1,3 acute ttp has a mortality rate of >90%, if left untreated.4
TAK Ratings Summary
TAK Quant Ranking